NASDAQ : ZYBT
Zhengye Biotechnology Holding Limited — Key statistics
Healthcare · Drug Manufacturers - Specialty & Generic · China
Last price 1.43 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 67.77M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 61.61M |
| Enterprise Value | 64.92M |
Dates
| Measure | Value |
|---|
| Earnings Date | Dec 11, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 7.39M |
| Shares Outstanding | 47.39M |
| Shares Change (YoY) | +3.69% |
| Shares Change (QoQ) | +0.14% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | 0.27% |
| Float | 6.26M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 3.70 |
| Forward PS | n/a |
| PB Ratio | 1.72 |
| P/TBV Ratio | 2.21 |
| P/FCF Ratio | 33.24 |
| P/OCF Ratio | 30.73 |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 3.90 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 35.03 |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 1.14 |
| Quick Ratio | 0.58 |
| Debt / Equity | 0.24 |
| Debt / EBITDA | n/a |
| Debt / FCF | 5.79 |
| Interest Coverage | -20.74 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -25.17% |
| Return on Assets (ROA) | -9.48% |
| Return on Invested Capital (ROIC) | -21.37% |
| Return on Capital Employed (ROCE) | -22.31% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | $61,846 |
| Profits Per Employee | -$37,090 |
| Employee Count | 269 |
| Asset Turnover | 0.25 |
| Inventory Turnover | 1.90 |
Taxes
| Measure | Value |
|---|
| Income Tax | 1.59M |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | n/a |
| 52-Week Price Change | -47.15% |
| 50-Day Moving Average | 1.48 |
| 200-Day Moving Average | 1.16 |
| Relative Strength Index (RSI) | 43.09 |
| Average Volume (20 Days) | 1,758,995 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 67,594 |
| Short Previous Month | 115,090 |
| Short % of Shares Out | 0.14% |
| Short % of Float | 1.08% |
| Short Ratio (days to cover) | 0.04 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 16.64M |
| Gross Profit | 3.41M |
| Operating Income | -10.08M |
| Pretax Income | -10.28M |
| Net Income | -9.98M |
| EBITDA | -6.38M |
| EBIT | -10.08M |
| Loss Per Share | -$0.21 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 7.42M |
| Total Debt | 10.73M |
| Net Cash | -3.32M |
| Net Cash Per Share | -$0.07 |
| Equity (Book Value) | 43.85M |
| Book Value Per Share | 0.75 |
| Working Capital | 2.42M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | 2.01M |
| Capital Expenditures | -151,590 |
| Depreciation & Amortization | 3.89M |
| Net Borrowing | -1.84M |
| Free Cash Flow | 1.85M |
| FCF Per Share | $0.04 |
Margins
| Measure | Value |
|---|
| Gross Margin | 20.51% |
| Operating Margin | -60.59% |
| Pretax Margin | -61.77% |
| Profit Margin | -59.97% |
| EBITDA Margin | -38.35% |
| EBIT Margin | -60.59% |
| FCF Margin | 10.59% |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -3.69% |
| Shareholder Yield | -3.69% |
| Earnings Yield | -16.21% |
| FCF Yield | 3.01% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 8.39 |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |